Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy | Zendy

Patrice Desvignes-Nickens | Zendy; Kent M Koprowicz | Zendy; Ruth McBride | Zendy; Koon Teo | Zendy; William S. Weintraub | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

Author(s) -

Patrice Desvignes-Nickens,

Kent M Koprowicz,

Ruth McBride,

Koon Teo,

William S. Weintraub

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1107579

Subject(s) - simvastatin , niacin , medicine , statin , cholesterol , residual risk , lipoprotein , endocrinology , cardiology

In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research